Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Sales (2021 - 2025)

InMed Pharmaceuticals has reported Return on Sales over the past 5 years, most recently at 0.02% for Q4 2025.

  • For Q4 2025, Return on Sales changed 0.0% year-over-year to 0.02%; the TTM value through Dec 2025 reached 0.02%, changed 0.0%, while the annual FY2025 figure was 0.02%, 0.0% changed from the prior year.
  • Return on Sales for Q4 2025 was 0.02% at InMed Pharmaceuticals, down from 0.02% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.0% in Q2 2023 and troughed at 0.16% in Q4 2021.
  • A 5-year average of 0.05% and a median of 0.02% in 2023 define the central range for Return on Sales.
  • Biggest five-year swings in Return on Sales: grew 15bps in 2023 and later fell -1bps in 2024.
  • Year by year, Return on Sales stood at 0.16% in 2021, then skyrocketed by 72bps to 0.04% in 2022, then surged by 73bps to 0.01% in 2023, then crashed by -94bps to 0.02% in 2024, then decreased by -7bps to 0.02% in 2025.
  • Business Quant data shows Return on Sales for INM at 0.02% in Q4 2025, 0.02% in Q3 2025, and 0.01% in Q2 2025.